BMS and Pfizer to start a new randamized controlled trial accessing the impact of atrial fibrillation screening on health outcomes in older individuals

Nov 16, 2019: PRINCETON, N.J. and Bristol-Myers Squibb-Pfizer Alliance announced the initiation of a new randomized controlled trial (GUARD-AF) for undiagnosed atrial fibrillation in elderly individuals.  The estimated case of AFib is about 8 million people in the U.S.  in 2019. https://www.pfizer.com/news/press-release/press-release-detail/bristol_myers_squibb_and_pfizer_announce_randomized_controlled_trial_to_evaluate_the_effect_of_atrial_fibrillation_screening_on_health_outcomes_in_older_individuals